Misplaced Pages

Pitt–Hopkins syndrome
Boy with Pitt–Hopkins syndrome showing the characteristic facial features.
Specialty	Psychiatry, Medical genetics

Pitt–Hopkins syndrome (PTHS) is a rare genetic disorder characterized by developmental delay, moderate to severe intellectual disability, distinctive facial features, and possible intermittent hyperventilation followed by apnea. Epilepsy (recurrent seizures)often occurs in Pitt-Hopkins. It is part of the clinical spectrum of Rett-like syndromes. Pitt-Hopkins syndrome is clinically similar to Angelman syndrome, Rett-syndrome, Mowat Wilson syndrome, and ATR-X syndrome.

As more is learned about Pitt–Hopkins, the developmental spectrum of the disorder is widening, and can also include difficulties with anxiety, autism, ADHD, and sensory disorders. It is associated with an abnormality within chromosome 18 which causes insufficient expression of the TCF4 gene. Those with PTHS have reported high rates of self-injury and aggressive behaviors usually related to autism and their sensory disorders.

PTHS has traditionally been associated with severe cognitive impairment, however true intelligence is difficult to measure given motor and speech difficulties. Thanks to augmentative communication and more progressive therapies, many individuals can achieve much more than initially thought. It has become clearer that there is a wider range of cognitive abilities in Pitt–Hopkins than reported in much of the scientific literature. No cure is known for Pitt-Hopkins syndrome, but it is possible to treat associated symptoms. Researchers have developed cell and rodent models to test therapies for Pitt–Hopkins.

PTHS is estimated to occur in 1:11,000 to 1:41,000 people.

Signs and symptoms

PTHS can be seen as early as childhood.

The earliest signs in infants is the lower face and the high nasal root.

The facial features are characteristic and include:

• Broad nasal bridge with bulbous tip
• Wide mouth
• Cupid's bow philtrum
• Prominent ears
• Thin eyebrows

Flat feet, overriding toes, and fetal pads are also common. Short stature and scoliosis occur frequently.

Other features of Pitt-Hopkins syndrome may include constipation and other gastrointestinal problems, an unusually small head (microcephaly), nearsightedness (myopia), eyes that do not look in the same direction (strabismus), short stature, and minor brain abnormalities

Adults who have PTHS may have trouble with their speech. Craniofacial features, which are important when diagnosing PTHS, become more visible as the person gets older.

Children with Pitt-Hopkins syndrome typically have a happy, excitable demeanor with frequent smiling, laughter, and hand-flapping movements. However, they can also experience anxiety and behavioral problems.

Gastrointestinal

Gastrointestinal difficulties are common in individuals with Pitt-Hopkins and can include constipation, reflux, and burping. Severe constipation often occurs over the entire lifespan. Breathing issues may cause air swallowing and associated pain. Low muscle tone can cause feeding issues at an early age.

Neurological

Epilepsy is not uncommon in Pitt-Hopkins and is reported in 37%-50% of cases. The onset of seizures can occur in infants or throughout adulthood. A variety of seizures can occur. Electroencephalographic (EEG) patterns can be typical or atypical, depending on the individual.

Magnetic resonance imaging (MRI) reveals that deviations in the brain may occur in individuals with Pitt-Hopkins. These can include a small corpus callosum, wide ventricles, and deviations in the posterior fossa. Many individuals with Pitt Hopkins can also have typical brain structures.

Musculoskeletal.

Minor hand and foot anomalies such as slender or small hands and feet, broad fingertips, clinodactyly, tapered fingers, transverse palmar crease, flat feet with hindfoot valgus deformity, overriding toes, and short metatarsals have been reported. Absent flexion creases of the thumbs may occur with thumb ankylosis. In one individual an absent thumb tendon was found during surgery .

Genetics

The genetic cause of this disorder was described in 2007. This disorder is due to a haploinsufficiency of the transcription factor 4 (TCF4) gene which is located on the long arm of chromosome 18 (18q21.2) The mutational spectrum appears to be 40% point mutations, 30% small deletions/insertions and 30% deletions. All appear to be de novo mutations. The risk in siblings is low, but higher than the general population due to parental germline mosaicism.

A Pitt–Hopkins-like phenotype has been assigned to autosomal recessive mutations of the contactin associated protein like 2 (CNTNAP2) gene on the long arm of chromosome 7 (7q33-q36) and the neurexin 1 alpha (NRXN1) gene on the short arm of chromosome 2 (2p16.3).

Malformations in the CNS can be seen in about 60 to 70% of patients on MRI scans.

Pitt–Hopkins patients with a TCF4 deletion can lack the syndrome's characteristic facial features.

Diagnosis

There is not a certain diagnostic criteria, but there are a few symptoms that support a diagnosis of PTHS. Some examples are: facial dysmorphism, early onset global developmental delay, moderate to severe intellectual disability, breathing abnormalities, and a lack of other major congenital abnormalities.

Zollino and colleagues defined diagnostic criteria based on characteristic features found in 75% of cases genetically confirmed for PTHS, termed cardinal features. If a person shows 9 cardinal features, they are classified as having PTHS.

It is possible that a phenotype resembling PTHS can occur without the mutation in the TCF4 gene. Mutations in the TCF4 gene do not always result in stereotypical Pitt-Hopkins syndrome.

Half of the individuals with PTHS are reported to have seizures, starting from childhood to the late teens.

Around 50% of those affected show abnormalities on brain imaging. These include a hypoplastic corpus callosum with a missing rostrum and posterior part of the splenium, with bulbous caudate nuclei bulging towards the frontal horns.

Electroencephalograms show an excess of slow components.

According to the clinical diagnosis. PTHS is in the same group as Pervasive Developmental Disorders.

When a patient is suspected of having PTHS, genetic tests looking at the TCF4 gene are typically done. Some argue for a genetic test to occur first, followed by a clinical assessment.

Differential diagnosis

PTHS is symptomatically similar to Angelman syndrome, Rett syndrome and Mowat–Wilson syndrome.

Angelman syndrome most closely resembles PTHS. Both have absent speech and a "happy" disposition. Of the differentials, Rett syndrome is the least close to PTHS. This syndrome is seen as a progressive encephalopathy. Both Angelman syndrome and Rett syndrome lack the distinctive facial features of PTHS. Mowat–Wilson syndrome is seen in early infancy and is characterized by distinctive facial abnormalities.

Treatment

There is no specific treatment for this condition. It is based on symptomatology. Since there is a lack of treatment, people with PTHS use behavioral and training approaches. Comorbidities may also be treated.

Care from a medical team including neurologists, ophthalmologists, pulmonologists, and gastroenterologists may be utilized.

Recommendations for developmental delay and intellectual disability in the U.S. (may differ depending on country):

• Early intervention program from newborn to age 3 will allow access to different therapies (occupational, physical, speech, and feeding).
• Developmental preschool through public school systems from ages 3 to 5. The child will need an evaluation before getting into the program, to see what kind of therapy is needed.
• From the ages 5–21 the child's school may create an IEP (based on the child's functions and needs). Children are encouraged to stay in school until at least the age of 21.

History

The condition was first described in 1978, by D. Pitt and I. Hopkins (The Children's Cottages Training Centre, Kew and Royal Children's Hospital, Melbourne, Australia) in two unrelated patients.

References

1. ^ Sweetser DA, Elsharkawi I, Yonker L, Steeves M, Parkin K, Thibert R (1993), Adam MP, Feldman J, Mirzaa GM, Pagon RA (eds.), "Pitt-Hopkins Syndrome", GeneReviews®, Seattle (WA): University of Washington, Seattle, PMID 22934316, retrieved 17 July 2024
2. Zweier C, Peippo MM, Hoyer J, Sousa S, Bottani A, Clayton-Smith J, et al. (May 2007). "Haploinsufficiency of TCF4 causes syndromal mental retardation with intermittent hyperventilation (Pitt-Hopkins syndrome)". American Journal of Human Genetics. 80 (5): 994–1001. doi:10.1086/515583. PMC 1852727. PMID 17436255.
3. Whalen S, Héron D, Gaillon T, Moldovan O, Rossi M, Devillard F, et al. (January 2012). "Novel comprehensive diagnostic strategy in Pitt-Hopkins syndrome: clinical score and further delineation of the TCF4 mutational spectrum". Human Mutation. 33 (1): 64–72. doi:10.1002/humu.21639. PMID 22045651. S2CID 9559486.
4. ^ Goodspeed K, Newsom C, Morris MA, Powell C, Evans P, Golla S (10 January 2018). "Pitt-Hopkins Syndrome: A Review of Current Literature, Clinical Approach, and 23-Patient Case Series". Journal of Child Neurology. 33 (3): 233–244. doi:10.1177/0883073817750490. ISSN 0883-0738. PMC 5922265. PMID 29318938.
5. "Pitt-Hopkins syndrome may point the way to autism treatments". Daniel R. Weinberger. May 2019.
6. "Pitt-Hopkins". National Center for Biotechnology Information. Retrieved 8 December 2009.
7. Watkins A, Bissell S, Moss J, Oliver C, Clayton-Smith J, Haye L, et al. (October 2019). "Behavioural and psychological characteristics in Pitt-Hopkins syndrome: a comparison with Angelman and Cornelia de Lange syndromes". Journal of Neurodevelopmental Disorders. 11 (1): 24. doi:10.1186/s11689-019-9282-0. PMC 6778364. PMID 31586495.
8. "A drug for autism? Potential treatment for Pitt-Hopkins syndrome offers clues; PTHS". The Conversation. 26 April 2019. Retrieved 10 July 2019.
9. ^ Sweetser DA, Elsharkawi I, Yonker L, Steeves M, Parkin K, Thibert R (1993). "Pitt-Hopkins Syndrome". In MP, Ardinger HH, Pagon RA, Wallace SE (eds.). GeneReviews. University of Washington, Seattle. PMID 22934316.
10. ^ Dean L (2012). "Pitt-Hopkins Syndrome". In Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520343. Bookshelf ID: NBK66129.
11. ^ "Pitt-Hopkins Syndrome". Definitions. Qeios. 2 February 2020. doi:10.32388/nb53oy. S2CID 161843893. Retrieved 16 October 2022.
12. "Pitt-Hopkins syndrome", Definitions, Qeios, 10 February 2020, doi:10.32388/l1967e
13. "Pitt-Hopkins syndrome", Definitions, Qeios, 10 February 2020, doi:10.32388/l1967e
14. ^ Zollino M, Zweier C, Van Balkom ID, Sweetser DA, Alaimo J, Bijlsma EK, et al. (18 February 2019). "Diagnosis and management in Pitt-Hopkins syndrome: First international consensus statement". Clinical Genetics. 95 (4): 462–478. doi:10.1111/cge.13506. hdl:2066/201958. ISSN 0009-9163. PMID 30677142.
15. Sweetser DA, Elsharkawi I, Yonker L, Steeves M, Parkin K, Thibert R (1993), Adam MP, Feldman J, Mirzaa GM, Pagon RA (eds.), "Pitt-Hopkins Syndrome", GeneReviews®, Seattle (WA): University of Washington, Seattle, PMID 22934316, retrieved 26 July 2024
16. Amiel J, Rio M, de Pontual L, Redon R, Malan V, Boddaert N, et al. (May 2007). "Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction". American Journal of Human Genetics. 80 (5): 988–993. doi:10.1086/515582. PMC 1852736. PMID 17436254.
17. Peippo M, Ignatius J (April 2012). "Pitt-Hopkins Syndrome". Molecular Syndromology. 2 (3–5): 171–180. doi:10.1159/000335287. PMC 3366706. PMID 22670138.
18. ^ Marangi G, Zollino M (September 2015). "Pitt-Hopkins Syndrome and Differential Diagnosis: A Molecular and Clinical Challenge". Journal of Pediatric Genetics. 4 (3): 168–176. doi:10.1055/s-0035-1564570. PMC 4918722. PMID 27617128.
19. ^ Sweatt JD (May 2013). "Pitt-Hopkins Syndrome: intellectual disability due to loss of TCF4-regulated gene transcription". Experimental & Molecular Medicine. 45 (5): e21. doi:10.1038/emm.2013.32. PMC 3674405. PMID 23640545.
20. Pitt D, Hopkins I (September 1978). "A syndrome of mental retardation, wide mouth and intermittent overbreathing". Australian Paediatric Journal. 14 (3): 182–4. doi:10.1111/jpc.1978.14.3.182. PMID 728011. S2CID 45629810.

External links

• Medicine

• Transcription factor deficiencies
• Syndromes affecting the eye
• Disorders causing seizures
• Syndromic autism
• Rare diseases
• Syndromes with ADHD